TELUS Health acquires Workplace Options, top provider of wellbeing services to Fortune 500 companies
TELUS Health combines digital-first innovation with Workplace Options' Employee and Family Assistance Program to transform employee wellbeing solutions
GTCR to invest US$200 million as part of the acquisition, bringing strategic healthcare industry expertise to accelerate TELUS Health's global growth and innovation
VANCOUVER, BC and TORONTO, May 14, 2025 /CNW/ - TELUS Corporation ("TELUS") (TSX: T) (NYSE: TU) today announced a strategic partnership with GTCR, a leading private equity investor with extensive expertise across the healthcare landscape, supporting TELUS Health's recently announced acquisition of Workplace Options. Last week, TELUS Health announced the acquisition of Workplace Options for cash of approximately $500 million (US$350 million), net of assumed debt of approximately $100 million (US$70 million). Workplace Options, a leading global provider of integrated employee wellbeing solutions across 200 countries and territories, further solidifies TELUS Health as an unparalleled force in the global wellbeing solutions market. Today, TELUS Health is one of the largest companies providing digital-first health and wellbeing services and solutions globally to empower individuals to live their healthiest lives. TELUS Health is now positioned to support clients across all channels and global verticals covering more than 150 million lives and growing.
"Today marks a transformative milestone in our global health technology journey," said Darren Entwistle, President and CEO of TELUS. "By uniting TELUS Health and Workplace Options, we are creating an unprecedented breadth of experience and expertise that will drive global consistency in Employee and Family Assistance Programs (EFAP) and Wellbeing Solutions in a way that is unmatched in our industry. This acquisition furthers TELUS Health's practice of partnering with providers, digital health organizations, health plans and employers to create a more robust and localized offering executed at a global scale. This powerful combination, underpinned by TELUS' extensive AI expertise, ability to draw on common technologies, trends and advancements will unlock high-quality health outcomes for all constituents in a way previously unrealized. With more than 40-years of investment experience within the healthcare vertical, we look forward to GTCR's investment on this acquisition, who will be a value-added partner, supporting our efforts to accelerate growth."
"This is more than an acquisition, it's an extension of our vision to build one of the most comprehensive suites of health and wellbeing solutions globally," said Navin Arora, Executive Vice-president, TELUS and President, TELUS Business Solutions, TELUS Health, TELUS Agriculture & Consumer Goods, and TELUS Partner Solutions. "With our differentiated and complementary products and services and a strong base of local and multinational clients worldwide, we're excited about unlocking significant growth opportunities, new revenue streams and powerful economies of scale."
Benefits of the transaction:
Establishes a global network of more than 180,000 providers across more than 200 countries and territories, positioning TELUS Health as a leader in the global employer health and wellbeing space.
Delivers a standardized model for providing customers with robust EFAP and wellbeing services, backed by industry-leading customer experience support, global scale and reach.
Brings together TELUS' robust infrastructure and leading networks with Workplace Options' strong digital capabilities, as well as TELUS Digital's AI expertise, providing TELUS Health with a unique competitive advantage in the global market.
"By joining forces with TELUS Health, we are aligning with an organization that shares our deep commitment to innovation in EFAP solutions and our focus on delivering exceptional value to the reseller community," said Alan King, CEO, Workplace Options. "This acquisition by TELUS Health marks an exciting new chapter, uniting us in our mission to scaling what matters most: care, connection and trust in the workplace. TELUS Health's leading digital innovation will enable us to deliver unparalleled wellbeing services, ultimately transforming the health and productivity landscape."
GTCR brings over four decades of healthcare investment expertise to this strategic collaboration, having executed more than 65 platform healthcare investments and 250 healthcare transactions. GTCR will invest US$200 million as part of this acquisition, leveraging their deep industry knowledge and proven track record of successful corporate partnerships. GTCR is positioned as a strategic ally in support of TELUS Health's continued growth ambitions, while their participation in the Workplace Options transaction establishes the foundation for a long-term, value-generating partnership.
"We are thrilled to partner with TELUS Health to support its continued growth by leveraging both our deep expertise in the healthcare sector and ability to structure a bespoke transaction to meet the needs of our partner," said Dean Mihas, Co-CEO and Managing Director, GTCR. "Providing flexible capital solutions to outstanding management teams, coupled with a partnership approach to helping drive value creation through industry insights and experience, is core to GTCR's approach to delivering value to our portfolio companies, investors and other stakeholders."
About TELUS Health
TELUS Health is on a mission to become the most trusted wellbeing company in the world by enhancing the overall efficiency of healthcare and championing workplace wellbeing. By integrating advanced healthcare technology with comprehensive employee support services, TELUS Health provides a holistic approach to primary and preventive health and wellbeing enhancing more than 150 million lives across more than 200 countries and territories. Our innovative digital health platforms, including electronic medical records (EMRs) and virtual care solutions, empower healthcare professionals, employers and governments to deliver personalized care efficiently. Our employee wellbeing programs empower individuals by offering extensive support through Employee and Family Assistance Programs (EFAPs), mental health resources, financial counselling and workplace wellness initiatives. At TELUS Health, we are committed to revolutionizing healthcare to ensure people receive the support they need and employees thrive both personally and professionally. Together, let's make the future friendly. For more information please visit: www.telushealth.com.
For media inquiries, please contact:
Marielle Hossack
TELUS Health
[email protected]
Investor Relations, please contact:
Ian McMillan
SOURCE TELUS Health
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 hours ago
- Globe and Mail
If I Had to Pick Just 1 Dividend Stock, This Is It
It's easy to focus on stocks' price movements because it's the most straightforward way to measure performance. However, a lot of money can be made from stocks beyond just price appreciation. The key is dividends. Dividends are a way for companies to reward shareholders for simply owning a stock and can compensate for slow (or no) stock price growth. Ideally, you'll get both stock price growth and dividends, creating a lucrative two-for-one. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » There are thousands of dividend stocks on the market, but they're not all created equal. There are dozens that I think highly of, but if I had to choose only one to invest in, it would be Coca-Cola (NYSE: KO). You'll never have to doubt Coca-Cola's dividend When it comes to dividend security, you'd have a hard time finding a more reliable stock than Coca-Cola. It has paid out a dividend since 1920, but more importantly, it has increased its annual dividend for 63 consecutive years. Only eight companies on the stock market have a longer streak. Coca-Cola's current quarterly dividend is $0.51, with a yield of around 2.7% (as of June 10). It's not an ultra-high yield that other S&P 500 stocks may have, but it's still more than double the current S&P 500 average. KO Dividend Yield data by YCharts Coca-Cola's dividend yield is lower than usual because its stock price has had an impressive start to 2025, up over 17%. This hasn't been the recent norm for Coca-Cola's stock, but it's a nice addition to its dividend. A business built to withstand any economic conditions Coca-Cola is as close to a recession-proof business as you'll find on the market, and it comes down to two things: products that sell no matter what and pricing power. Coca-Cola products are considered consumer staples, meaning they're everyday items that people purchase regardless of economic conditions. When money is tight, consumers typically delay upgrading electronics, put off vacations, or cook at home instead of dining out at restaurants. What they don't typically remove from the budget are Coca-Cola products. This doesn't mean Coca-Cola doesn't face headwinds or slowdowns; it absolutely does. However, it does mean its core business remains relatively stable through economic downturns. And when volume slows down, Coca-Cola has the pricing power to increase prices without losing customers. As an example, look at Coca-Cola's first quarter of this year. Although global unit case volume only grew 2% year over year, Coca-Cola's organic revenue (which doesn't take into account foreign currency impacts) grew 6%. The ability to adjust prices to compensate for volume is a testament to Coca-Cola's strong brand loyalty. "Just raise prices" isn't the best long-term strategy, but it's one to lean on when consumer spending slows. Coca-Cola never seems to gets complacent Despite the massive success of Coca-Cola's core products like its flagship Coca-Cola soda, Diet Coke, and Sprite, Coca-Cola has never seemed to get complacent. Will those brands be Coca-Cola's bread and butter for quite some time? Most likely. However, it's nice to have a suite of successful brands that can complement those. After owning around 400 brands, Coca-Cola realized there's power in a large portfolio, but only if you can still operate efficiently. With a large portion of its sales coming from a small portion of its portfolio, Coca-Cola cut its portfolio by roughly half in 2020. By trimming its portfolio, Coca-Cola has been able to simplify supply chain management and distribution, which is crucial for a company with hundreds of bottling partners and distribution in over 200 countries. The slimmed-down operations are also why its revenue can be significantly less than competitors like PepsiCo (which sells drinks and food products), yet its net income can be much higher. KO Revenue (Quarterly) data by YCharts This doesn't mean Coca-Cola shies away from acquiring brands; they're just more selective and focused on adapting to changing consumer preferences (low-calorie, plant-based, alcohol ready-to-drink, etc.). If you're investing in a stock for the long haul, make sure the company has the ability and willingness to adapt and not get complacent. Should you invest $1,000 in Coca-Cola right now? Before you buy stock in Coca-Cola, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Coca-Cola wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Edmonton Journal
21 hours ago
- Edmonton Journal
Jets sign defenceman Alfons Freij to three-year, entry-level contract
Article content The Winnipeg Jets have signed defenceman Alfons Freij to a three-year, entry-level contract, the team announced Saturday. The average annual value of the deal in the NHL is $975,000 US. Article content Friej, 19, played 29 games for Bjorkloven IF in the Swedish HockeyAllsvenskan and had eight points (two goals, six assists) and 12 penalty minutes. The six-foot-one, 192-pound blueliner also played five games for the Bjorkloven IF junior team in the J20 Nationell and had five points (two goals, three assists) and two PIMs. He added a pair of assists and four PIMs in two playoff games. Freij was Winnipeg's second-round pick (37th overall) in the 2024 NHL Draft. Article content Article content Latest National Stories
Montreal Gazette
a day ago
- Montreal Gazette
Opinion: U.S. vaccine funding cancellation is disastrous
With Donald Trump's second administration, disruptive news seems to arise on a daily basis. Most concerning for clinicians and health scientists in Canada and around the world was Trump's appointment of anti-vaccination advocate Robert F. Kennedy Jr. to the enormously influential position of secretary of health and human services. Kennedy's ideological dismantling of the U.S.'s vaunted health research apparatus has been at a speed that's surprising even to his most ardent critics. But his recent decision to cancel a nearly US$600-million contract with vaccine manufacturer Moderna may be among his most short-sighted and destructive moves, with ripple effects globally. The contract with the mRNA pioneer, signed under the Joe Biden administration, was meant to fund the development, testing and licensing of vaccines targeting particular flu strains, including the strain responsible for the dreaded avian flu, H5N1. Many scientists fear H5N1 could become the next world-stopping infectious disease pandemic. The main reason cited for the cancellation was concern for the safety and testing of mRNA vaccine technology. But the company's mRNA COVID vaccines are among the most tested and scrutinized medical products in human history. The withdrawal of the U.S. from efforts to produce an mRNA vaccine against H5N1 is indeed troubling. When it infects humans, H5N1 kills about 50 per cent of the time. Canada's only known domestically acquired human case of H5N1 to date was discovered in November. The current outbreak among dairy herds in the U.S. has spread to at least 17 states and more than 1,000 herds. The increasing number of domestic and wild animals found to be infected is worrying, suggesting that the dreaded mutation allowing easy human-to-human transmission is becoming more likely by the day. When that happens, many people will die, and many more will clamour for a vaccine. Luckily, we already have more than one licensed H5N1 vaccine based on older, non-mRNA technology. But their efficacy is largely unknown, and many of them are manufactured via incubating the virus inside live eggs. In the event of an avian flu pandemic, finding enough uninfected eggs to produce doses at scale could be problematic. More challenging is the lead time for manufacturing these traditional vaccines. At the very least, many months are needed, which is why the seasonal flu vaccine is often a poor match to circulating strains, resulting in middling efficacy. If an H5N1 pandemic is in our near future, it will not be possible to manufacture sufficient doses of the currently licensed vaccines quickly enough to protect everyone. The only proven vaccine technology capable of the kind of rapid production needed to quell a sudden pandemic is the mRNA platform. Five years of refinement over the course of the COVID era has afforded Moderna and Pfizer a kind of confident fluency in their development and deployment acumen. Other companies have since adopted the technology as well. Another consideration is viral mutation. If H5N1 makes the mutational leap to sustained human-to-human transmission, it will be because its genetic makeup will have changed enough to make that happen. In other words, the virus will be measurably different from that used to create the currently licensed formulations. The mRNA platform will be needed to quickly pivot to targeting the new viral formulation. It can do so with much more adeptness and fluidity than the lumbering egg- and cell-incubated vaccines currently stockpiled. Remember: the first COVID mRNA vaccine was finalized just 48 hours after scientists sequenced the genetic code of the virus that causes COVID. RFK Jr.'s decision to cancel this funding is short-sighted and seemingly driven by skewed and nonsensical anti-vax perceptions. It comes at a time when early clinical trials had already demonstrated the safety of Moderna's investigational pandemic influenza vaccine, called mRNA-1018. Perhaps this is an opportunity for other countries — such as Canada — to fill the funding void and claim the financial and societal benefits of this transformational technology.
